Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The effect of metformin versus placebo, including three insulin-analogue regimens with variating postprandial glucose regulation, on CIMT in T2DM patients - A randomized, multicenter trial.

Next Previous
Trial Profile

The effect of metformin versus placebo, including three insulin-analogue regimens with variating postprandial glucose regulation, on CIMT in T2DM patients - A randomized, multicenter trial.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 20 Jan 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin aspart (Primary) ; Insulin aspart/insulin protamine aspart (Primary) ; Insulin detemir (Primary) ; Metformin (Primary)
  • Indications Diabetic angiopathies; Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms CIMT

Most Recent Events

  • 01 Jan 2022 Results of a post hoc analysis assessing the effects of 18-months metformin versus placebo in combination with three insulin regimens on RNA and DNA oxidation in individuals with type 2 diabetes published in the Free Radical Biology and Medicine
  • 01 Sep 2021 Results of exploratory sub-study of the Copenhagen Insulin and Metformin Therapy trial (n=407) assessing long-term effects of metformin compared with placebo on whole body bone and body composition measures in patients with type 2 diabetes mellitus, published in the Osteoporosis International.
  • 16 Sep 2016 Results presented at the 52nd Annual Meeting of the European Association for the Study of Diabetes

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top